Citigroup analyst Itay Michaeli maintains Lear (NYSE:LEA) with a Neutral and raises the price target from $137 to $138.
Here’s How Much You Would Have Made Owning Horizon Therapeutics Stock In The Last 5 Years
Horizon Therapeutics (NASDAQ:HZNP) has outperformed the market over the past 5 years by 40.09% on an annualized basis…